The Celgene Co. (CELG) Downgraded by Vetr Inc. to “Buy”

The Celgene Co. (CELG) Downgraded by Vetr Inc. to “Buy”

Several other equities research analysts also recently issued reports on CELG. Cantor Fitzgerald set a $159.00 price objective on shares of Celgene and gave the stock a buy rating in a research note on Saturday, February 18th. Cowen and Company reissued an outperform rating and set a $150.00 target price on shares of Celgene in a research report on Wednesday, March 8th. Oppenheimer Holdings Inc. set a $148.00 target price on shares of Celgene and gave the stock a buy rating in a research report on Saturday, February 25th. Robert W. Baird reissued an outperform rating and set a $162.00 target price on shares of Celgene in a research report on Wednesday, January 11th. Finally, JPMorgan Chase & Co. reissued a buy rating on shares of Celgene in a research report on Saturday, February 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $139.05.

Vetr cut shares of Celgene Co. (NASDAQ:CELG) from a strong-buy rating to a buy rating in a research note published on Thursday, May 11th. Vetr currently has $132.90 target price on the biopharmaceutical company’s stock.

Celgene (NASDAQ CELG) opened at 118.73 on Thursday. Celgene has a 12 month low of $94.42 and a 12 month high of $127.64. The stock’s 50 day moving average price is $120.36 and its 200-day moving average price is $119.78. The stock has a market cap of $92.71 billion, a price-to-earnings ratio of 44.59 and a beta of 1.74. Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.21. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. During the same period in the previous year, the firm earned $1.32 earnings per share. Celgene’s revenue for the quarter was up 17.8% on a year-over-year basis. Equities analysts expect that Celgene will post $7.29 EPS for the current year.

Celgene (NASDAQ CELG) opened at 118.73 on Thursday. Celgene has a 12 month low of $94.42 and a 12 month high of $127.64. The stock’s 50 day moving average price is $120.36 and its 200-day moving average price is $119.78. The stock has a market cap of $92.71 billion, a price-to-earnings ratio of 44.59 and a beta of 1.74. In other Celgene news, Director James J. Loughlin sold 9,250 shares of Celgene stock in a transaction on Monday, May 1st. The stock was sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the completion of the transaction, the director now directly owns 32,169 shares of the company’s stock, valued at $3,988,956. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 14,033 shares of Celgene stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total value of $1,737,706.39. Following the transaction, the director now directly owns 73,109 shares of the company’s stock, valued at $9,053,087.47. The disclosure for this sale can be found here. 0.97% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dillon & Associates Inc. boosted its position in shares of Celgene by 2.5% in the third quarter. Dillon & Associates Inc. now owns 42,995 shares of the biopharmaceutical company’s stock worth $4,514,000 after buying an additional 1,040 shares during the last quarter. State of Wisconsin Investment Board boosted its position in shares of Celgene by 0.6% in the third quarter. State of Wisconsin Investment Board now owns 860,294 shares of the biopharmaceutical company’s stock worth $89,927,000 after buying an additional 4,810 shares during the last quarter. Eagle Ridge Investment Management raised its stake in shares of Celgene by 0.3% in the third quarter. Eagle Ridge Investment Management now owns 17,122 shares of the biopharmaceutical company’s stock worth $1,790,000 after buying an additional 51 shares during the period. Peregrine Capital Management LLC acquired a new stake in shares of Celgene during the third quarter worth $21,025,000. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Celgene by 17.7% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 133,899 shares of the biopharmaceutical company’s stock worth $1,751,000 after buying an additional 20,116 shares during the period. 77.68% of the stock is owned by institutional investors. Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CELG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”}); To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Celgene Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene Co. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment